Topoisomerase II (TOP2) has held the interest of researchers studying cancer owing to the discovery that it is targeted by active anticancer drugs, notably etoposide and doxorubicin (REF. 1). These studies showed that most clinically active drugs that target TOP2 generate enzymemediated DNA damage [2] [3] [4] . As etoposide and doxorubicin are highly active anticancer agents in many different clinical settings, the identification of a crucial target of these drugs was a major landmark in the pharmacology of anticancer drugs.
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Recent work has shown that there might be contexts in which the level of TOP2 predicts clinical activity, as well as many contexts in which it does not. An understanding of mechanisms of drug action and improved patient survival rates has led to an appreciation that clinical treatment with drugs that target TOP2 can lead to secondary malignancies. An important goal of present and future work is to maximize the therapeutic efficacy of TOP2-targeting agents and minimize the risks of secondary malignancy and other toxicities. This Review highlights recent work that is relevant to maximizing the potential of TOP2 as an anticancer drug target.
Inhibition of TOP2 activity by anticancer agents
Drugs targeting TOP2 are divided into two broad classes. The first class, which includes most of the clinically active agents, including etoposide, doxorubicin and mitoxantrone, leads to increases in the levels of TOP2-DNA covalent complexes. Because these agents generate lesions that include DNA strand breaks and protein covalently bound to DNA, they have been termed TOP2 poisons. A second class of compounds inhibits TOP2 catalytic activity but does not generate increases in the levels of TOP2 covalent complexes. Agents in this second class are thought to kill cells through the elimination of the essential enzymatic activity of TOP2 and are therefore termed TOP2 catalytic inhibitors (FIG. 1) .
There are several lines of evidence indicating the importance of the distinction between TOP2 poisons and TOP2 catalytic inhibitors. Studies in yeast and mammalian cells showed that resistance to TOP2 poisons is recessive, that is, the presence of a drug-resistant TOP2 allele in the presence of a drug-sensitive allele results in cells that are drug sensitive (reviewed in REFS 5, 6) . The importance of enzyme-mediated DNA damage was also shown by observations that TOP2 poisons rapidly elicit DNA damage responses such as phosphorylation of ataxia-telangiectasia mutated (ATM) and activation of downstream damage responses [7] [8] [9] . Resistance to TOP2-targeting drugs in mammalian cells is frequently associated with the reduced expression of TOP2 isoforms 6 , suggesting that resistance is mediated through a reduction in enzyme-mediated DNA damage, rather than through increasing the available enzyme activity (by this mechanism, resistance would arise from the increased expression of TOP2 isoforms).
The generation of high levels of TOP2-DNA covalent complexes has profound effects on cell physiology. TOP2 poisons effectively block transcription and replication. DNA strand breaks are rapidly detected following treatment with TOP2 poisons and most of the strand breaks are linked to proteins, as expected The pattern of responses observed with catalytic inhibitors of TOP2 differs from the pattern observed with TOP2 poisons, albeit with several important complications. Most catalytic inhibitors of TOP2 are not specific
, with the exception of bisdioxopiperazines. Although bisdioxopiperazines generate DNA damage responses following long-term exposure 13 , they do not produce a DNA damage response following short-term exposure [14] [15] [16] [17] . Importantly, in cell culture experiments, catalytic inhibitors of TOP2 antagonize the toxicity of TOP2 poisons 18 , indicating that the agents act by separable mechanisms. An important and still unanswered question is whether TOP2 inhibitors that are not poisons might be active anticancer agents. This issue is addressed in the concluding sections of this Review.
TOP2 poisons.
As shown in BOX 1, a diverse range of compounds leads to increased levels of DNA cleavage. The precise mechanism of action of TOP2 poisons remains an important unsolved question. It is instructive to consider the mechanism of camptothecins against topoisomerase I (TOP1) because several camptothecinprotein-DNA ternary structures have been solved 19, 20 . Camptothecins intercalate between the -1 and +1 bases of DNA in the ternary complex, in which the -1 base is the nucleotide that is covalently bound to TOP1. The intercalated drug makes several contacts with the protein by hydrogen bonding. The overall ternary complex is stabilized both by stacking interactions between the drug and the bases it inter calates between, and by the drug-protein interactions. Gratifyingly, the amino acids that interact with camptothecins can lead to camptothecin resistance when they are mutated 21 . The net result of the presence of the camptothecin is that, for TOP1, the 5′-hydroxyl is displaced relative to the 3′-phosphotyrosyl, thereby preventing re-ligation. This type of inhibition has been referred to as interfacial inhibition -the drug interacts at the interface between the protein and DNA 22 . A similar mechanism can be used to explain intercalating TOP2 poisons. The intercalator is positioned between the -1 and +1 bases and disrupts the geometry required for re-ligation after strand passage. This localization of TOP2 poisons was first suggested by an analysis of TOP2 cleavage sequence preferences obtained by treating purified TOP2 with defined DNA fragments in the presence of TOP2 poisons 23, 24 . This type of positioning has been directly shown using an analogue of mAMSA that can be photoactivated and phage T4 topoisomerase II (REF. 25 ) (in its reactions and range of inhibitors, the phage topoisomerase is more similar to eukaryotic TOP2 than to prokaryotic type II enzymes 26 ). The mAMSA derivative is found linked to the +1 base relative to DNA cleavage, suggesting that there is intercalation at the site of cleavage. Because the photoactivatable analogue of mAMSA does not react with DNA in the absence of TOP2, TOP2 has a role in stabilizing the position of this small molecule so that it can react with DNA. Although direct information has not been obtained with other intercalating agents, a clear base preference has been found at cleavage sites, and the strongest preferences are at either the -1 or +1 bases 27 . These results are consistent with the presence of an intercalator at a protein-DNA interface, and a major effect of the inhibitor being a change in the geometry of the residues required for re-ligating the DNA strand break. It is likely that this type of model also extends to non-intercalating TOP2 poisons 24 . For non-intercalating poisons, an initial drug-protein binary complex might be important for delivering the drug to a site where a stable ternary complex can be formed [28] [29] [30] . There are several important questions that remain when the interfacial inhibition model is applied to TOP2 poisoning. First, does the model imply that trapping double strand cleavage requires the action of two drug molecules at the site of cleavage? Osheroff and colleagues have argued that two etoposide molecules are required for increased double strand cleavage 31 . It is plausible that similar effects occur with intercalators, although this has not been examined carefully. It should be noted that double strand cleavage is not absolutely required for effective TOP2 poisons; single strand cleavage by TOP2 can also result in cytotoxicity 32 . Second, it has been suggested that many TOP2 poisons do not block re-ligation but instead generate high levels of TOP2-DNA covalent complexes by stimulating cleavage 33 . This mode of action is not easily explained by interfacial inhibition, and suggests that some agents can cause DNA or protein perturbations that lead to continuous cycles of cleavage.
What do we know about the protein determinants of TOP2 poisons? A standard approach to address this question has been the isolation of drug-resistant forms of the target enzyme. Although many drug-resistant
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• Topoisomerase II (TOP2) is the target of several important classes of anticancer drugs, including the epipodophyllotoxin etoposide and the anthracycline doxorubicin.
• Most clinically active drugs that target TOP2 kill cells by trapping an enzyme intermediate termed the covalent complex. Therefore, the principal action of the TOP2-targeting drugs that are currently used is to generate enzyme-mediated DNA damage.
• A recent structure of the breakage reunion domain of TOP2 bound to DNA has been determined. This structure is likely to be useful for understanding the protein determinants of the action of drugs targeting TOP2. A drug-protein-DNA ternary complex would be valuable but has not yet been determined.
• TOP2-mediated DNA damage is repaired by multiple pathways. This DNA damage includes DNA strand breaks and proteins that are covalently bound to DNA. Repair of TOP2-mediated damage requires double-strand break repair pathways and other pathways that are specific for the removal of protein-DNA adducts.
• Sensitivity to TOP2-targeting drugs depends in part on the levels of TOP2. Cells overexpressing TOP2 are hypersensitive to TOP2 poisons and cells expressing low levels of TOP2 are drug resistant. TOP2A is frequently co-amplified with ERBB2, which can lead to the development of tumours with increased levels of TOP2α.
• An important side effect of targeting TOP2 with TOP2 poisons is the formation of secondary malignancies that arise from drug-induced translocations. TOP2β might be the TOP2 isoform that is most responsible for the secondary malignancies caused by TOP2-targeting drugs.
• Anthracycline use is limited by cardiotoxicity. Although the mechanism of the cardiotoxicity is poorly understood, recent results suggest that anthracyclines that target TOP2β might contribute to cardiotoxicity. There might be considerable benefit to developing TOP2-targeting drugs that are specific for the TOP2α isoform.
• Catalytic inhibition of TOP2 could also be a useful anticancer strategy. New compounds are being developed to test this possibility. 34 . However, many of the mutants in TOP1 that led to camptothecin resistance were not understood until a three-dimensional structure of a drug-DNA-enzyme ternary complex was determined 35 . The newly described structure of TOP2 bound to DNA might be one step forward in helping to rationalize why specific mutants confer drug resistance 36 . For example, in previous structures, the TOPRIM domain was located far from the active site tyrosine. During cleavage and re-ligation, these two elements must interact and therefore must be close to each other. Because TOP2 poisons act at the point of cleavage and re-ligation, the relevant drugbinding pocket might be formed by residues that form both the TOPRIM and winged-helix domains (FIG. 2) . The hypothesis that the winged-helix and the TOPRIM domains come together to form a drug-binding pocket is supported by studies of fluoroquinolone action against prokaryotic Top2 enzymes. Fluoroquinolone-resistant mutations occur in both the TOPRIM and wingedhelix domains, and rarely occur in other parts of the protein (reviewed in REF. 37 ). Although this localization Topoisomerase II (TOP2) can be inhibited at several different points in the enzyme reaction cycle, which can have different biochemical and cellular consequences. One simple mode of inhibition is to inhibit a step early in the enzyme reaction cycle. For example, competitive inhibitors of ATP binding prevent strand passage and do not generate enzyme-mediated DNA damage. Although agents such as novobiocin and coumermycin (not shown) inhibit both prokaryotic and eukaryotic Top2 enzymes, they are either less potent and nonspecific (for example, novobiocin) or are poorly taken up by mammalian cells (for example, coumermycin). Similar effects would occur with inhibitors that prevent the binding of TOP2 to DNA such as aclarubicin. Agents that prevent DNA cleavage by TOP2 such as merbarone would also be expected to act as simple catalytic inhibitors. Although merbarone clearly prevents DNA cleavage by TOP2 (REF. 127 ), merbarone affects other targets besides TOP2. A second mode of inhibition is blocking the catalytic cycle after DNA is cleaved but before DNA re-ligation. This mode of inhibition occurs for most currently used TOP2 targeting agents, including anthracyclines and epipodophyllotoxins (such as etoposide), as well as for agents that target prokaryotic type II topoisomerases. These agents prevent enzyme turnover and are therefore strong inhibitors of catalytic activity; however, the most obvious effect of these inhibitors is the generation of high levels of TOP2-DNA covalent complexes. Therefore, these inhibitors generate DNA damage and interfere with many DNA metabolic events such as transcription and replication. As agents of this class convert TOP2 into an agent that induces cellular damage, they have been termed topoisomerase poisons. TOP2 can be inhibited after strand passage is completed but before ATP hydrolysis and dissociation of amino-terminal dimerization. Bisdioxopiperazines such as dexrazoxane (ICRF-187) inhibit both ATP hydrolysis and maintain the TOP2 structure as a closed clamp 74 . As is the case with TOP2 poisons, bisdioxopiperazines inhibit TOP2 catalytic activity mainly by blocking enzyme turnover. Although these agents are frequently termed catalytic inhibitors, they leave TOP2 trapped on DNA and might interfere with DNA metabolism in a manner that might be analagous to TOP2 poisons. Nonetheless, as bisdioxopiperazines are specific for TOP2, they are the most commonly used catalytic inhibitors of TOP2 in mammalian cells 143 . P i , inorganic phosphate. 
TOPRIM domain
A conserved domain found in topoisomerases, primases and other DNA metabolic enzymes. The TOPRIM domain adopts a Rossman fold, and is involved in divalent cation binding.
of mutations is consistent with a drug-binding pocket that consists of these two domains of the protein, direct localization of fluoro quinolones by structural approaches has not yet been accomplished. It is likely that structural studies with the bacterial type II topoisomerases will also be informative for understanding eukaryotic TOP2 poisons 38 . A complementary approach to isolating drugresistant mutants of TOP2 that has recently had some success has been to identify alleles of TOP2 that confer hypersensitivity to TOP2-targeting drugs. This approach has led to the identification of mutations that are specific for classes of TOP2 poisons; for example, hypersensitivity to etoposide and no change in sensitivity to intercalating agents, and might generate mutant proteins that are suitable for structural studies of drug binding 39, 40 .
Generation of DNA damage by TOP2: a requirement for processing TOP2-DNA covalent complexes. TOP1 trapped by camptothecin generates a reversible single strand DNA break. When a DNA polymerase collides with a trapped TOP1-DNA covalent complex, a non-protein-linked double strand break can be generated 41, 42 . Although TOP2 generates double strand breaks during its reaction cycle, the two subunits associate strongly, at least for the eukaryotic enzyme 43 . It is likely that either proteolytic or nucleolytic processing reactions are required to generate a double strand break. Because the trapped enzyme-DNA covalent complex is processed into a double strand break, any collision that provokes processing has the potential to generate double strand breaks. Therefore, ongoing DNA replication is not required to generate double strand breaks in cells treated with TOP2 poisons.
Box 1 | Many different classes of compounds target topoisomerase II
Drugs targeting topoisomerase II (TOP2) fall into two categories: TOP2 poisons and TOP2 catalytic inhibitors. Many TOP2 poisons have been shown to have anticancer activity. TOP2 poisons can be further subdivided into intercalating and non-intercalating poisons. The intercalators are a chemically diverse group, and include doxorubicin and other anthracyclines, mitoxantrone, mAMSA and a range of other compounds that are not currently in clinical use, such as amonafide and ellipticine
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. Other than their ability to intercalate in DNA, there is no obvious chemical similarity that could explain the ability of these compounds to trap TOP2. Importantly, some compounds such as oAMSA and ethidium bromide are unable to poison TOP2, suggesting that the intercalation of a small molecule is insufficient to trap TOP2 as a covalent complex on DNA 1, 111 . Some of the intercalating TOP2-targeting drugs, notably the anthracyclines, have a range of effects on cells, including many effects that are independent of their action against TOP2. For example, doxorubicin is known to produce free radicals, cause membrane damage and induce protein-DNA crosslinks. Whether TOP2 is the most important target of anthracyclines remains a controversial issue (reviewed in REF. 112 ), although some of the results presented in the main text support the hypothesis that TOP2 is the most relevant target for both clinical responses and cardiotoxicity. For alternative hypotheses, see Non-intercalating TOP2 poisons include the epipodophyllotoxins etoposide and teniposide, and fluoroquinolones, which are mainly active against prokaryotic type II topoisomerases. As non-intercalating TOP2 poisons do not interact strongly with DNA, it has been suggested that protein-drug interactions have key roles in the ability of TOP2 poisons to trap TOP2 covalent complexes 116, 117 . Several classes of compounds have been described that inhibit TOP2 activity but do not increase DNA cleavage. The most prominent are the bisdioxopiperazines such as ICRF-187, which non-competitively inhibit TOP2 ATPase activity and trap TOP2 as a closed clamp 74, 118, 119 . Other TOP2 catalytic inhibitors include novobiocin [120] [121] [122] , merbarone 123 and the anthracycline aclarubicin 124 . All three compounds have targets besides TOP2 (REFS 122, 125, 126) ; therefore, these compounds have not been useful for assessing the feasibility of catalytic inhibitors of TOP2 as anticancer therapeutics. Merbarone has attracted interest because it is the only agent that has been found to inhibit TOP2 cleavage of DNA but not affect protein-DNA binding 127 . QAP1 is a newly described purine analogue that was rationally designed to target TOP2 ATPase activity 80 . This compound might be particularly useful for assessing the effects of catalytic inhibition of TOP2. Several other catalytic inhibitors have been described; however, their detailed mechanisms of action have not been explored. Repair of TOP2-mediated damage must accomplish several tasks. Successful repair must effectively recognize a TOP2 complex as DNA damage rather than as an active enzyme that can dissociate from DNA. Repair then requires removal of the protein that is covalently bound to DNA and repair of the DNA strand breaks. The recognition of a trapped covalent complex as damage probably occurs because the TOP2 covalent complex blocks replication and transcription. One unusual aspect of TOP2 covalent complexes being recognized as DNA damage is that drug-protein-DNA complexes might remain reversible until processing intervenes. Therefore, if recognition and repair are not initiated, the TOP2 covalent complex can reverse without deleterious effects. However, once repair is initiated, the TOP2 covalent complex is probably irreversible, and cells are committed to either repair the DNA damage or die.
Nucleolytic excision of protein adducts. One way to remove protein-DNA adducts is to excise the lesion by nucleolytic digestion of the DNA that is covalently bound to the protein 44 (FIG. 3) . This type of repair has been observed for TOP1 covalent complexes by tyrosyl DNA phosphodiesterase I (TDP1) 45, 46 . This enzyme processes 3′-phosphotyrosyl peptides linked to DNA and leaves a 3′-phosphate product. Other nucleolytic enzymes have also been proposed that could remove 3′-phosphotyrosyl peptides from DNA [47] [48] [49] , although direct biochemical evidence has not yet been reported. TDP1 is highly conserved among eukaryotes but has not been found in prokaryotes. Although the original characterization of yeast Tdp1 indicated that this enzyme was specific for the removal of 3′-phosphotyrosyl peptides from DNA 50 , yeast TDP1 mutants were hypersensitive to etoposide, and the purified yeast protein could also remove 5′-phosphotyrosyl peptides from DNA 51 . Interestingly, mammalian cells lacking TDP1 activity are not hypersensitive to etoposide, and purified human TDP1 has minimal activity against TOP2-DNA covalent complexes (J.l.N., unpublished data). These results suggest that there are clear differences between the yeast and mammalian TDP1 proteins. Both the yeast and human proteins have been crystallized 52, 53 , and the active sites show few differences. The biochemical basis of the difference between the two proteins remains an unanswered question.
until recently, there has been little direct information about the nucleolytic removal of TOP2 covalently bound to DNA. However, processing of 5′-phosphotyrosyl-linked proteins (the same type of trapped complex formed by TOP2) is crucial for normal meiotic recombination. The processing of early intermediates of meiotic recombination might model the pathways that occur during the repair of drug-induced TOP2 damage in somatic cells. Spo11 is a type IIB topoisomerase homologue that initiates meiotic recombination. Although the details of the Spo11 reaction are poorly understood, the Spo11 protein becomes covalently bound to DNA by a 5′-phosphotyrosyl linkage 54, 55 . Spo11 is removed from the DNA, leading to the formation of a double strand break that is required for recombination. Because Spo11 linked to DNA closely resembles the DNA damage that arises from trapping TOP2, it is plausible that the pathways that remove Spo11 might also function in repairing TOP2-mediated damage. In yeast, nucleasedeficient alleles of the MRN complex genes MRE11 and RAD50 are unable to remove Spo11 from DNA 56 . In addition, yeast SAE2 encodes an endonuclease that is required for Spo11 removal [57] [58] [59] . Mammalian homologues of Sae2, termed retinoblastoma-binding protein 8 (RBBP8, also known as CTIP), have recently been identified, and they also have key functions in processing recombination intermediates 60, 61 . Thus RBBP8 and the MRN complex are good candidates for endonucleolytic processing of covalent complexes of DNA with either TOP2 or Spo11. Keeney and colleagues applied a new assay in yeast using tagged versions of Spo11 to identify potential nucleolytic processing pathways 62 . After immunoprecipitating the tagged Spo11 and characterizing the DNA covalently bound to the protein, they found a specific small DNA associated with Spo11. They suggested that this was the product of endonucleolytic removal of Spo11. The nucleolytic product required both wild-type Mre11 and Sae2, suggesting that it was a bona fide processing intermediate. Although a processing intermediate was also detected in yeast cells treated with etoposide by examining labelled Top2, the processing was not dependent on either Mre11 or Sae2. An important qualification in the experiments with etoposide is the lack of clear evidence that the detected product was a processing intermediate. Nonetheless, the results strongly indicate that an endonucleolytic pathway is one important pathway that is available for repairing TOP2-mediated DNA damage. These results are also supported by studies in a bacterial model system using SbcCD, a bacterial nuclease that is related to the MRN complex proteins, which has been shown to remove protein covalently bound to DNA 44, 63 . Recent experiments using fission yeast have provided direct support for the hypothesis that Mre11 and Sae2 have direct roles in removing Top2 covalently bound to DNA. Hartsuiker and colleagues used physical assays similar to those described above for Spo11 removal. They showed that treating mre11 and ctp1 mutants of Schizosaccharomyces pombe with the epipodophyllo toxin derivative TOP53 resulted in increased levels of Top2 covalent complexes compared with isogenic wild-type strains 64 . This work is particularly important because it provides the first direct evidence for nucleolytic processing of a topoisomerase covalent complex in eukaryotic cells.
Although the MRe11-RBBP8 pathway is clearly involved in nucleolytic processing of TOP2 covalent complexes, it is likely to be one of several different nucleo lytic pathways involved in processing. For example, genetic studies in Saccharomyces cerevisiae and S. pombe suggest that the XPG homologue RAD2 (RAD13 in S. pombe) also plays a part in repairing Top2 covalent complexes. Repair of TOP1 covalent complexes involves multiple repair pathways 65 , and a similar complexity for removing TOP2 covalent complexes is also likely.
Degradation of TOP2.
A second distinct pathway for processing TOP2 damage depends on the proteolytic degradation of covalently bound TOP2 as a first step in processing 66 . liu and colleagues found that treatment of Hela cells with teniposide led to the rapid depletion of TOP2, especially the TOP2β isozyme. Degradation of TOP2β depended on ubiquitylation and could be inhibited by proteasomal inhibitors. Interestingly, transcriptional inhibitors could also prevent TOP2β degradation. These results suggested that a response to transcriptional blockade by TOP2 poisons is the targeted degradation of TOP2β. However, an alternative plausible explanation for these results is that the trapping of TOP2 covalent complexes leads to TOP2β degradation independently of whether it is trapped on DNA. To exclude this possibility, subsequent experiments connected the degradation of TOP2β to the generation of a DNA damage signal. Quiescent cells downregulate TOP2α and typically only express TOP2β. Therefore, post-mitotic neurons were treated with etoposide in the presence of other inhibitors. In quiescent cells, TOP2β is degraded in response to etoposide. Concomitantly, there is an induction of both γH2AX phosphorylation and autophosphorylation of ATM at Ser1981 (REF. 67); both proteins are involved in the response to DNA damage. Treatment with either a proteasomal or transcriptional inhibitor prevented TOP2β depletion and also prevented both γH2AX phosphorylation and ATM autophosphorylation. These experiments showed that TOP2β degradation is needed for a DNA damage-inducing signal in non-dividing cells. A simple explanation is the DNA double strand breaks are not generated at a high level in quiescent cells in the absence of proteolysis.
Recent results have also suggested that the protease pathway acts against trapped TOP2α complexes 68 . As was observed for TOP2β, TOP2 poisons induce the degradation of TOP2α, although the overall level of degradation is substantially lower than for TOP2β. The degradation could be blocked by either proteasomal or transcriptional inhibitors, but not by the polymerase inhibitor aphidicolin. DNA damage signalling was attenuated by all of the inhibitors but was not completely abolished. Finally, p53 induction was not substantially Following recognition of topoisomerase II (TOP2) covalent complexes (perhaps by collision with replication forks), collision with other tracking proteins such as RNA polymerase or other undiscovered surveillance processes, repair can be initiated by proteolysis or by nucleolytic processing. Proteolysis will not completely remove the protein because the phosphotyrosyl linkage to the DNA cannot be removed by proteases. Therefore, after proteolysis, a nucleolytic processing step is still required. As illustrated, the product of nucleolytic processing is a DNA molecule containing a double strand break. Note that TOP2 can be trapped as a single strand break, as the two subunits break DNA in an independent but coordinated process 144 . Processing of a covalent complex with a single strand break could generate either a single strand break or a double strand break. Recent experiments have shown that a TOP2 enzyme that can only generate single strand breaks can confer cytotoxicity in the presence of TOP2 poisons 32 . For simplicity, the trapped structure that is illustrated shows a double strand break. In the case of a double strand break, repair is carried out mainly by homologous recombination or non-homologous end joining. Repair can also take place by error-prone single strand annealing pathways. The error-prone repair of TOP2-generated DNA double strand breaks can generate translocations that lead to secondary malignancies. The repair of single strand breaks that arise from TOP2 covalent complexes has not been fully explored.
affected by any of the inhibitors. These results imply that there are at least two distinct pathways involved in processing TOP2 damage: a transcription-dependent pathway, in which processing is initiated by proteolysis; and a replication-dependent pathway, in which processing is mainly proteasome independent.
What is the effect of these pathways on cytotoxicity? Treatment of cells with either a proteasomal or transcriptional inhibitor plus a TOP2 poison has little effect on cell survival 68 . By contrast, aphidicolin partly reduces cytotoxicity 68 . The effect of aphidicolin on etoposide cytotoxicity is not as pronounced as the complete block of camptothecin cytotoxicity by aphidicolin 42, 69 . Nonetheless, the role of replication in increasing the cytotoxicity of etoposide suggests that this agent might also be cell cycle dependent 6 . Finally, proteolysis will not completely degrade all of the bound TOP2 -the tyrosine and perhaps a few additional amino acids will remain covalently attached to DNA and require nucleolytic repair as described above.
The two pathways described above are both concerned with removal of TOP2. For both pathways, the product of the reaction is frequently a double strand break. It is likely that the repair of double strand breaks follows the patterns of double strand breaks induced by other agents, such as ionizing radiation or endonuclease cleavage. Cells lacking non-homologous end joining (NHeJ) are clearly hypersensitive to TOP2-mediated damage (TABLE 1) . The importance of homologous recombination in repairing TOP2 damage in mammalian cells is less clear; however, some mutants that show defects in homologous recombination are hypersensitive to etoposide 70, 71 , and treatment with etoposide stimulates both NHeJ and homologous recombination 72 . Because NHeJ clearly repairs some TOP2 damage, this pathway is likely to have a role in the oncogenic rearrangements that are induced by TOP2-targeting agents 73 .
Catalytic inhibitors of TOP2. Several classes of compounds have been described that target TOP2 without stabilizing TOP2 covalent complexes. The most important class of compounds, the bisdioxopiperazines, include ICRF-159, ICRF-187 and MST-16. These drugs have two activities: they are potent chelating agents and they block TOP2 in the catalytic cycle after strand passage but before the hydrolysis of the second ATP 74, 75 . At this point in the reaction cycle, TOP2 encircles the strand that the enzyme had cleaved; this is the point in the reaction cycle at which TOP2 is blocked by non-hydrolysable ATP analogues 76 . Bisdioxopiperazines have modest anti-tumour activity and their clinical use is primarily for reducing the cardiotoxicity of anthracyclines. However, they are important tools for studying the effects of TOP2 inhibition because they are the most specific TOP2 inhibitors that are not TOP2 poisons.
The question of whether bisdioxopiperazines are pure catalytic inhibitors has been raised recently. First, bisdioxopiperazines trap TOP2 on DNA, even though the trap is a non-covalent clamp around DNA. Results in yeast suggest that the trapped clamp can lead to cytotoxicity independently of loss of catalytic activity 77 . The clamp affects chromatin structure 16 , and alterations in chromatin structure might play a part in cytotoxicity, again independently of loss of TOP2 activity. In addition to the potential deleterious effects of TOP2 clamps on DNA, it has also been suggested that bisdioxopiperazines can trap TOP2 covalent complexes 78 . This is a surprising result because bisdioxopiperazines do not provoke the DNA damage responses that are generated by drugs such as etoposide. liu and colleagues have shown that bisdioxopiperazine trapping of TOP2 as a closed clamp on DNA leads to degradation. The degradation is specific for TOP2β, and is blocked by transcriptional inhibitors 79 . However, even if the closed clamp form of TOP2β can block transcription, treatment of cells with bisdioxopiperazine does not lead to degradation of the large subunit of RNA polymerase II, as occurs with other types of DNA damage. As Snapka and colleagues found that the denaturation conditions needed to trap TOP2 covalent complexes differed from those used with conventional poisons, the observed damage could be partially induced by the denaturation conditions.
It would be useful to have available other catalytic inhibitors of TOP2 that act by different mechanisms. A particularly useful class of inhibitors would be potent specific ATP-competitive inhibitors of TOP2 (improved versions of novobiocin). Inhibitors of this class would not interfere with DNA metabolism, except by causing a loss of TOP2 activity. Recently, a rationally designed ATP competitor inhibitor, QAP1, was synthesized and was shown to inhibit both TOP2α and TOP2β (REF. 80 ). Although cellular activity of this compound has not yet been described, QAP1 can reduce the DNA damage responses induced by doxorubicin, which is consistent with the action of this agent as a TOP2 catalytic inhibitor. Agents such as QAP1 are likely to be useful both for exploring the cellular consequences of the loss of TOP2 activity and addressing whether catalytic inhibition of TOP2 is an effective and safe anticancer strategy.
Targeting TOP2 in anticancer therapy
The ability of TOP2 to generate DNA damage in the presence of TOP2-targeting agents led to the hypothesis that an important determinant of drug sensitivity was the overall level of TOP2. early experiments with cell lines selected for drug resistance in vitro were consistent with this hypothesis; cells overexpressing TOP2 were drug hypersensitive and cells with reduced levels of detectable TOP2 were resistant to TOP2 poisons 5, 81 . Similar results were obtained using the expression of short sense or antisense RNAs derived from TOP2A, followed by selection for resistance to etoposide. Several antisense constructs led to reductions of TOP2α protein levels and resistance to multiple classes of TOP2 poisons 82 . These experiments showed that targeted changes in TOP2 levels were sufficient to confer resistance to multiple classes of TOP2 poisons. A more recent set of experiments using short hairpin RNA (shRNA) technology extended these observations to an in vivo setting 83 . A library of shRNAs was screened for genes conferring resistance to doxorubicin. Three genes were identified that could lead to doxorubicin resistance: TP53, CHEK2 and TOP2A. In addition to showing that a principal target of doxorubicin in vivo is TOP2, which was a point of long-standing contention, the model system of using a library of shRNAs has the potential for identifying other genes that confer resistance to TOP2-targeting drugs.
If increased levels of TOP2 lead to hypersensitivity to TOP2-targeting drugs, then tumours expressing higher levels of TOP2 might be expected to be particularly good candidates for therapy using TOP2 poisons. For most classes of cancer, there have been equivocal results when the clinical outcome is compared with TOP2 levels 6 . However, patients with amplified ERBB2 often showed good responses to drugs that target TOP2, especially anthracyclines. As TOP2A is located close to ERBB2 on chromosome 17, the TOP2A copy number was assessed in samples with ERBB2 amplification. In several cases, co-amplification of TOP2A was observed, with a good correlation of increased sensitivity to various TOP2 poisons [84] [85] [86] . Amplification of TOP2A has several interesting properties. In general, amplification is specific for tumours that have amplified ERBB2, but also occurs in some breast tumours that lack this amplification 87 . TOP2A and ERBB2 are independent amplicons in the sense that the copy number of TOP2A and ERBB2 frequently differ 88 . One way this might occur is if ERBB2 is amplified first, followed by a secondary round of amplification that includes TOP2A. Interestingly, there are also deletions of TOP2A as well as amplifications. Although one could predict that the deletions of TOP2A would reduce anthracycline sensitivity, in some cases, the deletion is also associated with positive responses 87 . Whether TOP2A amplification leads to higher TOP2 protein levels is controversial. An important caveat of studies that examine TOP2 levels is that most of the studies used immunohistochemistry, which is certainly less sensitive and quantifiable than the fluorescence in situ hybridization that is used to study gene amplification.
Although the role of TOP2A amplification in conferring sensitivity to anthracyclines continues to be examined, it has been suggested that anthracyclines fail to provide a long-term benefit in tumours in which TOP2A is amplified 89 . It is unusual for chemosensitivity to be conferred by an amplified gene. Typically, amplification is thought to confer resistance and provide a selective advantage to drug-treated cells. In this situation, amplification confers sensitivity, and it is likely that treatment with anthracyclines selects for cells that have lost TOP2A amplification. As anthracyclines induce DNA damage, it is possible that replication blocks might lead to alterations in TOP2A copy number. Given the importance of TOP2α for cells to proceed through mitosis, it would be interesting to determine whether there is any relationship between TOP2α levels and sensitivity to anti-mitotic agents such as taxanes.
Obstacles to increased use of TOP2 therapeutics Although TOP2-targeting drugs are active in many contexts, there are important negative consequences of their use that are especially crucial for this class of agents. The most important consequences arise from the observations that treatment with TOP2-targeting drugs can result in a wide range of secondary malignancies. The first recognition that TOP2 poisons could lead to secondary malignancies came from acute myeloid leukaemia as a complication of chemotherapy regimens that included etoposide and teniposide [90] [91] [92] [93] . A large body of evidence supports the hypothesis that TOP2 poisons have a high potential to generate translocations that can lead to secondary malignancies (reviewed in REFS 94, 95;  for a different view, see REF. 96) .
A new insight into the secondary malignancies that are induced by TOP2-targeting drugs has come from studies that used a transgenic mouse model in which Top2b was specifically ablated in skin. use of organ-specific ablation was needed because Top2b-null mice are inviable. etoposide applied to skin can generate malignancies, mainly melanomas. In skin lacking TOP2β, etoposide-induced melanomas are reduced in frequency 97 . loss of TOP2β also led to reduced levels of NHeJ induced by etoposide. Taken together, these results suggest that TOP2β is responsible for an important fraction of malignancies induced by etoposide. A plausible model is that TOP2β is trapped on DNA, perhaps in non-replicating cells. Proteasomal degradation uncovers a double strand break, which will be repaired by NHeJ, leading to oncogenic translocations in some cases.
Whether bisdioxopiperazines influence the induction of secondary leukaemias has been the subject of intense debate. In a trial for paediatric Hodgkin's disease, it was reported that adding bisdioxopiperazines to a regimen that included etoposide and doxorubicin led to a slight increase in secondary malignancies 98 , although most of the reported effects were below statistical significance [98] [99] [100] . A more recent paediatric trial in acute lymphoblastic leukaemia found no increased risk of secondary malignancies when bisdioxopiperazines were added to regimens containing TOP2 poisons 101 . An approach that has been frequently used in clinical trials is to combine several different TOP2-targeting drugs, especially etoposide and an anthracycline. As noted in BOX 1, there has been controversy over whether anthracyclines mainly act against TOP2 or against other targets. The action of anthracyclines against other targets could provide an important rationale for combining these compounds with other TOP2 inhibitors. However, the different toxicity profiles -for example, the absence of cardiotoxicity with epipodophyllotoxins -provide an additional important justification for combining different TOP2-targeting agents.
There are cases in which combinations might be well justified on mechanistic grounds. The combination of a TOP1 and a TOP2 inhibitor has been of particular interest. The rationale for this combination was originally based on the hypothesis that these drugs partially inhibit the catalytic activity of topoisomerases, and that, because TOP1 and TOP2 have overlapping functions in DNA metabolism, targeting both enzymes might increase anti-tumour activity. It was also suggested that the combination of a TOP1 and a TOP2 poison would help to prevent mechanism-based drug resistance, as resistance to camptothecins can be due to downregulation of TOP1, thereby leading to hypersensitivity to etoposide owing to a possible increase in TOP2 expression to compensate for TOP1 downregulation. Early trials of combinations of etoposide and topotecan or irinotecan had concerns caused about toxicity and complicated schedule dependence [131] [132] [133] [134] . More recent results have been more promising [135] [136] [137] . Agents that interfere with DNA repair pathways are likely to be candidates for combination therapy with TOP2-targeting drugs. Bortezomib is a small molecule that inhibits proteasome degradation and would be expected to block the proteasome-dependent pathway of repairing TOP2 covalent complexes. Bortezomib has been tested in combination with etoposide and doxorubicin 105, 138, 140 . Inhibitors of the DNA-dependent protein kinase catalytic subunit have also been described 141, 142 and have been shown to sensitize cells to etoposide 104 .
TOP2β might also be the villain in anthracyclineinduced cardiomyopathy. Bisdioxopiperazines (ICF-187 in this example) have been widely used as a cardioprotectant against anthracycline-induced cardiomyopathy. The mechanism of cardioprotection had been widely thought to be due to anthracycline-induced generation of reactive oxygen species 102 . In cardiac myocyte culture, anthracyclines induce a DNA damage signal that can be blocked by bisdioxopiperazines. The DNA damage signal can be blocked by the proteasomal inhibitors bortezomib and MG132. Importantly, the DNA damage signal induced by anthracyclines can also be attenuated in mouse embryonic fibroblasts (MeFs) derived from Top2b-null mice compared with MeFs that express Top2b
103
. As described above, bisdioxopiperazines lead to degradation of TOP2β. The effect seen in Top2b-null MeFs indicates that protection might arise from specific degradation of the enzyme, preventing toxic damage.
Exploiting sensitivity to TOP2-targeting drugs TOP2 poisons generate DNA damage that interferes with crucial cellular processes and lead to types of damage that require the interplay of several repair pathways. It is likely that alterations in repair capabilities are a major determinant of the in vivo response to TOP2-targeting drugs. An important goal is the ability to specifically disrupt pathways in cancer cells, leading to an improved clinical response. This concept is central to designing new ways of using TOP2-targeting agents and in rationally designing combinations of TOP2-targeting drugs with agents that target other processes. Although there are experimental drugs targeting repair pathways -for example, an inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which has been shown to confer hypersensitivity to TOP2 poisons 104 -further exploitation of this concept will require new small molecules targeting repair pathways and an improved ability to assess repair capability
. One pathway that might be closer to clinical exploitation is the proteasome-dependent repair pathway. The proteasomal inhibitor bortezomib has been tested in combination with anthracyclines and has shown some potential 105, 106 .
The future of TOP2 as a drug target Is there a need for new and different TOP2 drugs? The first answer to this question is a resounding yes, as targeting TOP2 is clearly successful in a wide range of contexts. It is clear from broad clinical experience that TOP2-targeting drugs can be safely and effectively combined with many other agents. The TOP2-targeting drugs in clinical use were identified not on the basis of their activity against TOP2, but mainly on empirical anti-tumour activity. Therefore, rational screening would be expected to lead to potent and specific TOP2 poisons. It would be desirable to know whether greater potency and specificity would improve clinical responses to TOP2-targeting drugs. At the time etoposide and doxorubicin were approved for use, we did not know of the existence of TOP2β. The results reviewed in this article suggest that targeting TOP2β leads to several undesirable consequences and has little clear benefit. The negative effects of targeting TOP2β include the induction of cardiotoxicity and it could potentially have a major role in secondary malignancies. However, there are potential benefits of targeting TOP2β, especially the ability to kill non-proliferating cells. Although targeting TOP2β might contribute to toxicity, it might also be important for eliminating cancer stem cells.
An important question is whether isotype-specific TOP2 poisons can be identified, as TOP2α and TOP2β share catalytic mechanisms and have a high degree of amino acid homology in their catalytic domains. It has been previously suggested that the intercalators mAMSA and mitoxantrone confer cytotoxicity mainly owing to targeting TOP2β (REF. 107 ). More recently, a new inter calator NK314 has been reported to be highly specific for TOP2α (REFS 108, 109) . Toyoda and colleagues also suggested that etoposide and doxorubicin cause greater levels of cytotoxicity by targeting TOP2α. Taken together, these results suggest that it might be possible to design agents specific for TOP2α, and these agents with both greater anti-tumour activity and reduced toxicity might be beneficial.
The search for improved TOP2-targeting drugs will require further advances in both the biochemistry and structural biology of drug action. Although the structures that have already been determined have provided important insights into the biochemistry of TOP2, the only structure of TOP2 bound to a drug that has been determined is the ATPase domain of TOP2 bound to ICRF-187 (REF 110) . The key to understanding the biochemistry of a drug such as etoposide is the determination of a ternary complex between the drug, protein and DNA. It is hoped that the structures of the breakage and reunion domains of TOP2α and TOP2β, especially their DNA-bound forms, will be solved soon.
An interesting question related to drug development is whether catalytic inhibitors of TOP2 might be active anticancer agents. Much of the literature on the action of TOP2 poisons implicitly assumes that they inhibit TOP2 activity. Compared with many other enzyme inhibitors, all of the currently described TOP2-targeting agents have poor potency (for example, the K i of etoposide for TOP2 is in the 5-20 μM range and the K i for ICRF-193 is in the 1-2 μM range). The availability of crystal structures provides the tools for addressing whether TOP2 inhibition will be a valuable strategy and also those needed to answer many important biological questions.
The recent biological insights in transcription, replication and checkpoint control also offer ways to better understand drug action and resistance. Because cancer cells are present with altered topoisomerase levels, whether by amplification or changes in gene regulation, these alterations provide an opportunity for improving therapy. Finally, active anticancer therapy requires an understanding of how cancer cells survive, and topoisomerases are central to many core biological functions.
